Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Invest New Drugs

Search In Journal Title:

Abbravation: Investigational New Drugs

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1007/bf02084047

Search In DOI:

ISSN

1573-0646

Search In ISSN:
Search In Title Of Papers:

Publication biases and phase II trials investigati

Authors: Nicolas Penel Antoine Adenis
Publish Date: 2008/10/18
Volume: 27, Issue: 3, Pages: 287-288
PDF Link

Abstract

The aim of this study was to determine which parameter may affect impact factor IF of journals publishing reports of phase II trial P2T investigating molecular targeted therapies MTT We reviewed 74 reports of P2Ts investigating MTT imatinib n = 55 sorafenib n = 11 sunitinib n = 5 dasatinib n = 3 issued between 1/2002 and 6/2008 As a result we found that the final result of the trial itself was the most important parameter that was related to IF as the medianIF was significantly lower for negative trials than for positive trials 271 vs 614 p = 0004

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
  2. Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial
  3. Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens
  4. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
  5. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
  6. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
  7. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
  8. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
  9. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells
  10. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
  11. Deactylase inhibition in myeloproliferative neoplasms
  12. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
  13. In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118
  14. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
  15. Blackberry-induced hand-foot skin reaction to sunitinib
  16. A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
  17. (+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9
  18. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects
  19. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
  20. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
  21. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
  22. ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities
  23. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
  24. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
  25. Pretargeting of necrotic tumors with biotinylated hypericin using 123 I-labeled avidin: evaluation of a two-step strategy
  26. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
  27. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil
  28. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
  29. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
  30. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
  31. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats
  32. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
  33. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
  34. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells
  35. Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
Search Result: